Towards improved quality of life in multiple sclerosis

Canbex Therapeutics is dedicated to treating spasticity in multiple sclerosis (MS) and potentially other disorders. Spasticity is a debilitating and painful symptom of MS that consists of involuntary spasms of limbs and torso. The goal of the Canbex lead programme is to set a new standard in the treatment of spasticity, through improved tolerability.

The company’s lead compound, VSN16R, is currently in Phase I human safety trials.

Investors in Canbex include MS Ventures, the corporate venture arm of Merck KGaA; the Wellcome Trust; "Fast Forward", the drug development arm of the US National Multiple Sclerosis Society; University College London (UCL Business PLC); and Esperante Ventures.

Our goal is to improve the quality of life for people with multiple sclerosis though a well-tolerated treatment for spasticity.